Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of depression, neuropathic pain, and other potential CNS pathological conditions. The company is also developing LevoCap ER, an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab, an oral dosage form of the opioid analgesic buprenorphine; and MepiGel, an orphan drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.
IPO Year:
Exchange: NASDAQ
Website: relmada.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/5/2024 | $23.00 → $1.00 | Outperform → Neutral | Mizuho |
| 9/17/2024 | $3.50 → $13.00 | Hold → Buy | Jefferies |
| 6/5/2024 | $3.00 → $2.00 | Neutral → Sell | Goldman |
| 10/14/2022 | $81.00 → $8.00 | Buy → Neutral | Goldman |
| 10/14/2022 | $90.00 → $10.00 | Buy → Hold | Truist |
| 10/14/2022 | Buy → Neutral | Guggenheim | |
| 10/13/2022 | $64.00 → $7.00 | Outperform → Perform | Oppenheimer |
| 12/20/2021 | $50.00 → $42.00 | Outperform | SVB Leerink |
| 11/18/2021 | $50.00 | Buy | Mizuho |
CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", or "the Company")), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Monday, May 12, 2025 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2025 and recent business progress. Conference Call and Webcast Information: Date: Monday, May 12, 2025 at 4:30 PM ETParticipant Dial-in (US): 1-877-407-0792Participant Dial-in (International): 1-201-689-8263Conference: 13753596Webcast Access: Click Here A replay of the webcast will be available in the
90% of patients achieved high grade disease-free status at any time point with NDV-01, demonstrating strong proof-of-concept for sustained-release "GEM/DOCE" formulation* NDV-01 showed promising clinical activity in BCG-naïve and BCG-unresponsive patients, with favorable overall tolerability Data to be reviewed at Investor Event on April 28, 2025 at 4:30 PM ET CORAL GABLES, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company")), a clinical-stage biotechnology company, today announced that positive initial data from the Phase 2 study of NDV-01 showed that 90% of patients achieved high-grade disease-free status at any time point
CORAL GABLES, Fla., April 27, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company")), a clinical-stage biotechnology company, today announced the presentation of an abstract at the American Urology Association (AUA2025), taking place from April 26-29th in Las Vegas. Abstract OverviewAbstract Title: Prospective Open Label Study to Evaluate the Safety and Efficacy of intravesical sustained release Gemcitabine Docetaxel combination (NDV-01) in High Risk NMIBCSession: Clinical Trials in Progress: Bladder CancerLocation: Hall C, The Square, Learning LabPresentation Date: April 28, 2025Presentation Time 10:04 AM PT to 10:12 AM PT About NDV-01NDV-01 is an
April 28th AUA data presentation to highlight study in patients with high-grade non-muscle invasive bladder cancer (HG-NMIBC) Virtual event to be held on April 28, 2025 at 4:30 PM ET CORAL GABLES, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company")), a clinical-stage biotechnology company, today announced it will host a virtual key opinion leader (KOL) event on Monday, April 28, 2025 at 4:30 PM ET. To register, please click here. The event will feature Boris Chertin, MD (Department of Urology, Shaare Zedek Medical Center) and Yair Lotan, MD (UT Southwestern Medical Center), who will join Relmada's management to discuss topline eff
CORAL GABLES, Fla., April 14, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company")), a clinical-stage biotechnology company, today announced the presentation of an abstract at the American Urology Association (AUA2025), taking place from April 26-29th in Las Vegas. Abstract OverviewAbstract Title: Prospective Open Label Study to Evaluate the Safety and Efficacy of intravesical sustained release Gemcitabine Docetaxel combination (NDV-01) in High Risk NMIBCSession: P2 (Paradigm-Shifting)Presentation Date: April 28, 2025Presentation Time 10:04 AM PT About NDV-01NDV-01 is an investigational, innovative sustained-release formulation of two complementa
CORAL GABLES, Fla., April 14, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company")), a clinical-stage biotechnology company, today announced the presentation of an abstract at the American Urology Association (AUA2025), taking place from April 26-29th in Las Vegas. Abstract OverviewAbstract Title:Prospective Open Label Study to Evaluate the Safety and Efficacy of Safety and Efficacy of intravesical sustained release Gemcitabine Docetaxel combination (NDV-01) in High Risk NMIBC: P2 on Apr 25Session:P2 (Paradigm-Shifting)Presentation Date:April 28, 2025Presentation Time10:04 AM PT About NDV-01NDV-01 is an investigational, innovative sustained-rele
Expect Topline Phase 2 data for NDV-01 for high-grade non-muscle invasive bladder cancer (HG-NMIBC), to be presented at AUA 2025 in April Advancing novel neurosteroid, sepranolone, towards Phase 2b study in Tourette syndrome with plans for evaluation in other compulsion-related disorders, including Prader-Willi Syndrome Cash balance of $44.8 million as of December 31 2024 Management hosting conference call and webcast today at 4:30 PM ET CORAL GABLES, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company")), a clinical-stage biotechnology company, today provided a corporate update and announced preliminary and unaudited financial re
CORAL GABLES, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", or "the Company")), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Thursday, March 27, 2025 at 4:30 PM ET to discuss recent business progress and financial results for the fourth quarter ended December 31, 2024. Conference Call and Webcast Information: Date: Thursday, March 27, 2025 at 4:30 PM ETParticipant Dial-in (US): 1-877-407-0792Participant Dial-in (International): 1-201-689-8263Conference: 13751458Webcast Access: Click Here A replay of the webcast will be av
NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer (NMIBC, U.S. prevalence of ~600,000 patients, with ~62,000 newly diagnosed patients annually) Topline efficacy and safety Phase 2 data expected to be reported at the American Urological Association meeting (AUA), being held April 26-29, 2025 in Las Vegas NDV-01 has the potential to be a first-line therapy for NMIBC, presenting attractive clinical benefits for clinicians and patients CORAL GABLES, Fla., March 25, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", or "the Company")), a
Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from Asarina Pharma AB Phase 2a results signaled improvement in Tourette symptoms, quality of life and robust overall safety, supporting Sepranolone as a new potential first line treatment option for TS Sepranolone (isoallopregnanolone) is a first-in-class compound from new subgroup of neurosteroids known as GAMSAs- GABAA Modulating Steroid Antagonists - acting selectively on the GABAA pathway, potentially alleviating the negative effect of Allopregnanolone in Tourette syndrome and other compulsive disorders CORAL GABLES, Fla., Feb. 06, 2025 (G
CORAL GABLES, Fla., Jan. 12, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ:RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of Fabiana Fedeli, Chief Investment Officer Equities, Multi Asset and Sustainability, at M&G Investments, one of the United Kingdom's largest and longest established investment houses, as an independent director to the Company's Board of Directors. Ms. Fedeli has extensive knowledge of international capital markets, sustainability, governance and corporate strategy
CORAL GABLES, Fla., Jan. 9, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ:RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of Cedric O'Gorman MD as the Company's Chief Medical Officer. Dr. O'Gorman will lead medical, clinical and regulatory functions in support of the Company's late-stage REL-1017 development program. Dr. O'Gorman brings to Relmada more than two decades of life sciences experience in clinical development, medical affairs and medical strategy, with significant expertise
Company Continues Commercial Preparations in Advance of Phase III Clinical Trial Readouts for REL-1017 in Major Depressive Disorder Expected in 2022 CORAL GABLES, Fla., July 21, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ:RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of John Hixon to a newly created position as Head of Commercial. Mr. Hixon has over 36 years of commercial planning and marketing experience within the biopharmaceutical industry. "My due diligence performed before joi
424B5 - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
8-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
8-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
10-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
8-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
8-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
8-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
8-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
8-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
8-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)
SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)
SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)
SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)
SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)
SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)
SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)
SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)
SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)
SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", or "the Company")), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Monday, May 12, 2025 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2025 and recent business progress. Conference Call and Webcast Information: Date: Monday, May 12, 2025 at 4:30 PM ETParticipant Dial-in (US): 1-877-407-0792Participant Dial-in (International): 1-201-689-8263Conference: 13753596Webcast Access: Click Here A replay of the webcast will be available in the
Expect Topline Phase 2 data for NDV-01 for high-grade non-muscle invasive bladder cancer (HG-NMIBC), to be presented at AUA 2025 in April Advancing novel neurosteroid, sepranolone, towards Phase 2b study in Tourette syndrome with plans for evaluation in other compulsion-related disorders, including Prader-Willi Syndrome Cash balance of $44.8 million as of December 31 2024 Management hosting conference call and webcast today at 4:30 PM ET CORAL GABLES, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company")), a clinical-stage biotechnology company, today provided a corporate update and announced preliminary and unaudited financial re
CORAL GABLES, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", or "the Company")), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Thursday, March 27, 2025 at 4:30 PM ET to discuss recent business progress and financial results for the fourth quarter ended December 31, 2024. Conference Call and Webcast Information: Date: Thursday, March 27, 2025 at 4:30 PM ETParticipant Dial-in (US): 1-877-407-0792Participant Dial-in (International): 1-201-689-8263Conference: 13751458Webcast Access: Click Here A replay of the webcast will be av
Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from Asarina Pharma AB Phase 2a results signaled improvement in Tourette symptoms, quality of life and robust overall safety, supporting Sepranolone as a new potential first line treatment option for TS Sepranolone (isoallopregnanolone) is a first-in-class compound from new subgroup of neurosteroids known as GAMSAs- GABAA Modulating Steroid Antagonists - acting selectively on the GABAA pathway, potentially alleviating the negative effect of Allopregnanolone in Tourette syndrome and other compulsive disorders CORAL GABLES, Fla., Feb. 06, 2025 (G
Pre-planned Phase 3 Reliance II interim analysis, anticipated by YE 2024, could represent an important de-risking event for REL-1017 and the Company Phase 1 study for REL-P11 for metabolic disease expected to begin by YE 2024 Cash position of $54.1 million provides runway through key near-term milestones, into 2025 Management hosting conference call and webcast today at 4:30 PM ET CORAL GABLES, Fla., Nov. 7, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, ", Relmada", , ", the Company", )), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for th
Pre-planned Phase 3 Reliance II interim analysis, anticipated by YE 2024, could represent an important de-risking event for REL-1017 and the Company Phase 1 study for REL-P11 for metabolic disease expected to begin by YE 2024 Cash position of $54.1 million provides runway through key near-term milestones, into 2025 Management hosting conference call and webcast today at 4:30 PM ET CORAL GABLES, Fla., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company")), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided
CORAL GABLES, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada")), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced plans to host a conference call and webcast on Thursday, November 7, 2024 at 4:30 PM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2024. Conference Call and Webcast Information:Date: Thursday, November 7, 2024 at 4:30 PM ETParticipant Dial-in (US): 1-800-717-1738Participant Dial-in (International): 1-646-307-1865Conference ID Code: 60579Webcast Access: Click Here A replay of the webcast will be available in the Investors
Outcome of pre-planned Reliance II interim analysis anticipated by YE 2024 Enrollment in Phase 3 Reliance II study expected to be completed by YE 2024 Preparations on track to initiate Phase 1 study for REL-P11 for metabolic disorders by YE 2024 Cash position of $70.4 million provides runway through key milestones, into 2025 Management hosting conference call and webcast today at 4:30 PM ET CORAL GABLES, Fla., Aug. 7, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, ", Relmada", , ", the Company", ))), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial res
Outcome of pre-planned Reliance II interim analysis anticipated by YE 2024 Enrollment in Phase 3 Reliance II study expected to be completed by YE 2024 Preparations on track to initiate Phase 1 study for REL-P11 for metabolic disorders by YE 2024 Cash position of $70.4 million provides runway through key milestones, into 2025 Management hosting conference call and webcast today at 4:30 PM ET CORAL GABLES, Fla., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company"))), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial
CORAL GABLES, Fla., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada"))), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced plans to host a conference call and webcast on Wednesday, August 7, 2024 at 4:30 PM ET to discuss recent business progress and financial results for the second quarter ended June 30, 2024. Conference Call and Webcast Information:Date: Wednesday, August 7, 2024 at 4:30 PM ETParticipant Dial-in (US): 1-800-717-1738Participant Dial-in (International): 1-646-307-1865Conference: 39584Webcast Access: Click Here The conference call utilizes the "Call me™" technology https://emport
Mizuho downgraded Relmada Therapeutics from Outperform to Neutral and set a new price target of $1.00 from $23.00 previously
Jefferies upgraded Relmada Therapeutics from Hold to Buy and set a new price target of $13.00 from $3.50 previously
Goldman downgraded Relmada Therapeutics from Neutral to Sell and set a new price target of $2.00 from $3.00 previously
Goldman downgraded Relmada Therapeutics from Buy to Neutral and set a new price target of $8.00 from $81.00 previously
Truist downgraded Relmada Therapeutics from Buy to Hold and set a new price target of $10.00 from $90.00 previously
Guggenheim downgraded Relmada Therapeutics from Buy to Neutral
Oppenheimer downgraded Relmada Therapeutics from Outperform to Perform and set a new price target of $7.00 from $64.00 previously
SVB Leerink reiterated coverage of Relmada Therapeutics with a rating of Outperform and set a new price target of $42.00 from $50.00 previously
Mizuho initiated coverage of Relmada Therapeutics with a rating of Buy and set a new price target of $50.00
Goldman resumed coverage of Relmada Therapeutics with a rating of Buy and set a new price target of $78.00